Filana Therapeutics, Inc. (FLNA) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-0.10x
Filana Therapeutics, Inc. (FLNA) has a Cash Flow-to-Debt Ratio of -0.10x as of June 2026, meaning its operating cash flow of $-3.85 Million could theoretically repay 0% of its total liabilities ($40.29 Million) in one year. See how financially flexible is Filana Therapeutics, Inc. to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-0.10x
Operating CF / Total Liabilities
Operating Cash Flow
$-3.85 Million
USD
Total Liabilities
$40.29 Million
USD
Data as of
Jun 2026
Most recent filing
Filana Therapeutics, Inc. Cash Flow-to-Debt Ratio (2022–2025)
Historical debt coverage capacity for Filana Therapeutics, Inc. across 4 annual periods. For the full cash flow conversion analysis, see FLNA operating cash flow.
Annual Cash Flow-to-Debt Ratio for Filana Therapeutics, Inc. (2022–2025)
Year-by-year debt coverage analysis for Filana Therapeutics, Inc..
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.73x | $-32.25 Million | $43.95 Million | ▲ +92.6% |
| 2024 | -9.88x | $-116.93 Million | $11.83 Million | ▼ -71.1% |
| 2023 | -5.78x | $-82.03 Million | $14.20 Million | ▲ +45.6% |
| 2022 | -10.63x | $-77.51 Million | $7.29 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.